Novartis and the Drugs for Neglected Diseases initiative, a not-for-profit research and development organization, have signed a collaboration and license agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers.
Read More
Health Rss 